ACS Combinatorial Science
Research Article
2007, 23, 79−101. (b) Nathan, P.; Zweifel, M.; Padhani, A. R.; Koh,
D.-M.; Ng, M.; Collins, D. J.; Harris, A.; Carden, C.; Smythe, J.; Fisher,
N.; Taylor, N. J.; Stirling, J. J.; Lu, S.-P.; Leach, M. O.; Rustin, G. J. S.;
Judson, I. Phase I trial of combretastatin A4 phosphate (CA4P) in
combination with bevacizumab in patients with advanced cancer. Clin.
Cancer Res. 2012, 18, 3428−3439. (c) Eskens, F. A. L. M.; Tresca, P.;
Tosi, D.; Van Doorn, L.; Fontaine, H.; Van der Gaast, A.; Veyrat-
Follet, C.; Oprea, C.; Hospitel, M.; Dieras, V. A phase I
pharmacokinetic study of the vascular disrupting agent ombrabulin
(AVE8062) and docetaxel in advanced solid tumours. Br. J. Cancer
2014, 110, 2170−2177.
and concentrated under reduced pressure. The crude product
was purified by silica gel chromatography.
ASSOCIATED CONTENT
* Supporting Information
■
S
Experimental details about synthesis and characterization of
compounds, biological and computational methods, copies of
1HNMR, and 13C NMR spectra of all new compounds. This
material is available free of charge via the Internet at http://
(10) (a) Treguier, B.; Hamze, A.; Provot, O.; Brion, J. D.; Alami, M.
Expeditious synthesis of 1,1-diarylethylenes related to isocombretas-
tatin A-4 (isoCA-4) via palladium-catalyzed arylation of N-
tosylhydrazones with aryl triflates. Tetrahedron Lett. 2009, 50, 6549−
6552. (b) Hamze, A.; Veau, D.; Provot, O.; Brion, J. D.; Alami, M.
Palladium-catalyzed Markovnikov terminal arylalkynes hydrostanna-
tion: Application to the synthesis of 1,1-diarylethylenes. J. Org. Chem.
2009, 74, 1337−1340. (c) Brachet, E.; Hamze, A.; Peyrat, J. F.; Brion,
J. D.; Alami, M. Pd-catalyzed reaction of sterically hindered hydrazones
with aryl halides: Synthesis of tetra-substituted olefins related to iso-
combretastatin A4. Org. Lett. 2010, 12, 4042−4045.
AUTHOR INFORMATION
Corresponding Authors
Funding
Our laboratory (Biocis UMR 8076 is a member of the
laboratory of excellence LERMIT supported by a grant from
ANR (ANR-10-LABX-33).
■
Notes
(11) (a) Mousset, C.; Giraud, A.; Provot, O.; Hamze, A.; Bignon, J.;
Liu, J. M.; Thoret, S.; Dubois, J.; Brion, J. D.; Alami, M. Synthesis and
antitumor activity of benzils related to combretastatin A-4. Bioorg. Med.
Chem. Lett. 2008, 18, 3266−3271. (b) Rasolofonjatovo, E.; Provot, O.;
Hamze, A.; Rodrigo, J.; Bignon, J.; Wdzieczak-Bakala, J.; Desravines,
D.; Dubois, J.; Brion, J.-D.; Alami, M. Conformationnally restricted
naphthalene derivatives type isocombretastatin A-4 and isoerianin
analogues: Synthesis, cytotoxicity and antitubulin activity. Eur. J. Med.
Chem. 2012, 52, 22−32. (c) Messaoudi, S.; Hamze, A.; Provot, O.;
Treguier, B.; De Losada, J. R.; Bignon, J.; Liu, J. M.; Wdzieczak-Bakala,
J.; Thoret, S.; Dubois, J.; Brion, J. D.; Alami, M. Discovery of isoerianin
analogues as promising anticancer agents. ChemMedChem. 2011, 6,
488−497.
The authors declare no competing financial interest.
ACKNOWLEDGMENTS
■
The Authors gratefully acknowledge support of this project by
CNRS, University Paris Sud and by La Ligue Nationale Contre
le Cancer throughout an Equipe Labellisee 2014 grant. M.L.
thanks the French Ministry of Research for a PhD fellowship.
REFERENCES
■
(1) Jordan, M.; Wilson, L. In The Role of Microtubules in Cell Biology,
Neurobiology, and Oncology; Fojo, T., Ed.; Humana Press: Totowa, NJ,
2008; p 47−81.
́
(12) (a) Messaoudi, S.; Treguier, B.; Hamze, A.; Provot, O.; Peyrat,
J.-F.; De Losada, J. R.; Liu, J.-M.; Bignon, J.; Wdzieczak-Bakala, J.;
Thoret, S.; Dubois, J.; Brion, J.-D.; Alami, M. Isocombretastatins A
versus combretastatins A: The forgotten isoCA-4 isomer as a highly
promising cytotoxic and antitubulin agent. J. Med. Chem. 2009, 52,
4538−4542. (b) Hamze, A.; Giraud, A.; Messaoudi, S.; Provot, O.;
Peyrat, J.-F.; Bignon, J.; Liu, J.-M.; Wdzieczak-Bakala, J.; Thoret, S.;
Dubois, J.; Brion, J.-D.; Alami, M. Synthesis, biological evaluation of
1,1-diarylethylenes as a novel class of antimitotic agents. Chem-
MedChem. 2009, 4, 1912−1924.
(2) Giavazzi, R.; Bonezzi, K.; Taraboletti, G. In The Role of
Microtubules in Cell Biology, Neurobiology, and Oncology; Fojo, T., Ed.;
Humana Press: Totowa, NJ, 2008; p 519−530.
(3) Jordan, M. A.; Wilson, L. Microtubules as a target for anticancer
drugs. Nat. Rev. Cancer 2004, 4, 253−265.
(4) Cormier, A.; Knossow, M.; Wang, C.; Gigant, B. In Methods in
Cell Biology; Leslie, W., John, J. C., Eds.; Academic Press: Burlington,
MA, 2010; Vol. Vol. 95, p 373−390.
(5) Snyder, J. P.; Nettles, J. H.; Cornett, B.; Downing, K. H.; Nogales,
E. The binding conformation of Taxol in β-tubulin: A model based on
electron crystallographic density. Proc. Natl. Acad. Sci. U.S.A. 2001, 98,
5312−5316.
(13) Lawson, M.; Hamze, A.; Peyrat, J. F.; Bignon, J.; Dubois, J.;
Brion, J. D.; Alami, M. An efficient coupling of N-tosylhydrazones with
2-halopyridines: Synthesis of 2-alpha-styrylpyridines endowed with
antitumor activity. Org. Biomol. Chem. 2013, 11, 3664−3673.
(6) Ravelli, R. B. G.; Gigant, B.; Curmi, P. A.; Jourdain, I.; Lachkar,
S.; Sobel, A.; Knossow, M. Insight into tubulin regulation from a
complex with colchicine and a stathmin-like domain. Nature 2004,
428, 198−202.
(7) Pettit, G. R.; Singh, S. B.; Hamel, E.; Lin, C. M.; Alberts, D. S.;
Garcia-Kendall, D. Isolation and structure of the strong cell growth
and tubulin inhibitor combretastatin A-4. Experientia 1989, 45, 209−
211.
́
(14) Treguier, B.; Rasolofonjatovo, E.; Hamze, A.; Provot, O.;
Wdzieczak-Bakala, J.; Dubois, J.; Brion, J.-D.; Alami, M. Synthesis of 2-
(1-phenylvinyl)benzofurans and 2-(1-phenylvinyl)indoles as antimi-
totic agents by a tandem palladium-assisted coupling-cyclization
reaction between 1-phenylvinyl iodides and ortho-substituted
arylalkynes. Eur. J. Org. Chem. 2011, 4868−4876.
(15) For recent representative examples, see: (a) Malamas, M. S.;
Sredy, J.; Moxham, C.; Katz, A.; Xu, W.; McDevitt, R.; Adebayo, F. O.;
Sawicki, D. R.; Seestaller, L.; Sullivan, D.; Taylor, J. R. Novel
benzofuran and benzothiophene biphenyls as inhibitors of protein
tyrosine phosphatase 1B with antihyperglycemic properties. J. Med.
Chem. 2000, 43, 1293−1310. (b) Li, L.; Berthelette, C.; Chateauneuf,
A.; Ouellet, M.; Sturino, C. F.; Wang, Z. Potent and selective 5-LO
inhibitor bearing benzothiophene pharmacophore: Discovery of MK-
5286. Bioorg. Med. Chem. Lett. 2010, 20, 7440−7443. (c) Wang, S.;
Beck, R.; Blench, T.; Burd, A.; Buxton, S.; Malic, M.; Ayele, T.; Shaikh,
S.; Chahwala, S.; Chander, C.; Holland, R.; Merette, S.; Zhao, L.;
Blackney, M.; Watts, A. Studies of benzothiophene template as potent
factor IXa (FIXa) inhibitors in thrombosis. J. Med. Chem. 2010, 53,
(8) (a) Siemann, D. W.; Chaplin, D. J.; Walicke, P. A. A review and
update of the current status of the vasculature-disabling agent
combretastatin-A4 phosphate (CA4P). Expert Opin. Invest. Drugs
2009, 18, 189−197. (b) Rajak, H.; Kumar Dewangan, P.; Patel, V.;
Kumar Jain, D.; Singh, A.; Veerasamy, R.; Chander Sharma, P.; Dixit,
A. Design of combretastatin A-4 analogs as tubulin targeted vascular
disrupting agent with special emphasis on their cis-restricted isomers.
Curr. Pharm. Des. 2013, 19, 1923−1955. (c) Tron, G. C.; Pirali, T.;
Sorba, G.; Pagliai, F.; Busacca, S.; Genazzani, A. A. Medicinal
chemistry of combretastatin A4: Present and future directions. J. Med.
Chem. 2006, 49, 3033−3044.
(9) (a) Cai, S. X. Small molecule vascular disrupting agents: Potential
new drugs for cancer treatment. Recent Pat. Anti-Cancer Drug Discovery
́ ̌
1465−1472. (d) Aleksic, M.; Bertosa, B.; Nhili, R.; Uzelac, L.; Jarak, I.;
H
dx.doi.org/10.1021/co500115b | ACS Comb. Sci. XXXX, XXX, XXX−XXX